Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 62-71

  Fossa S D ^a   Brausi, S M ^a   Horenblas, S ^a   Hall, R R ^a   Hetherington, J W ^a   Aaronson, N ^a   De Prijck, L ^a   Collette, L ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FLUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN THERAPY; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT FAILURE;

EID: 0035148171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.62     Document Type: Article

References (28)

1. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
2. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
3. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy
4. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
5. Reporting results of cancer treatment
6. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: A subanalysis of EORTC trial 30853
7. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
8. Eligibility and response guidelines for phase ii clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
9. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
10. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer
11. Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate
12. Benefits of combination therapy with flutamide in patients relapsing after castration
13. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer
14. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
15. Medical adrenalectomy for advanced prostatic cancer: Clinical and hormonal effects
16. Aminoglutethimide in advanced prostatic carcinoma
17. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
18. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
19. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
20. Low-dose hydrocortisone in chronic fatigue syndrome: A randomised crossover trial
21. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
22. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
23. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer
24. Management of hormone refractory prostate cancer: Current standards and future prospects
25. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial
26. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic cancer: DAPROCA study 9002
27. Comparison of the effects of high dose estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: An interim analysis of EORTC-GU Group study no. 30865